Abstract: Described herein are materials and methods for the conversion of a non-volatile form of 3-sulfanyl-1-hexanol (3SH) to free 3SH during a brewing process.

Abstract: An object of the present invention is to provide an extract capable of contributing to the improvement of the liquor taste of a beverage. The extract contains phenethyl alcohol and acetaldehyde, wherein a ratio of phenethyl alcohol content to acetaldehyde content (phenethyl alcohol content/acetaldehyde content) is 14 to 1,000.

Abstract: The present invention relates to mesoporous silica particles functionalized with at least one group having an acidic functionality and/or at least one group having a hydrophobic functionality anchored to the silica by means of a silicon-oxygen bond. The acidic functionality is preferably an alkyl group bearing a group selected from —SO3H, —COOH, —PO(OH)2. The hydrophobic functionality is preferably a saturated, linear alkyl group. The invention also relates to the use of the mesoporous silica particles for the removal of proteins from and/or the reduction of the concentration of several metals in a beverage having a pH lower than 4, preferably wine, beer, cider, and a combination thereof.

Abstract: Treatment eggs accommodated in recess parts are kept in a culture environment, and imaging units prepared at fixed positions with respect to recess parts continuously or intermittently capture images including the treatment eggs accommodated in these recess parts. Determination of growth of the treatment eggs is made for egg images including the imaged treatment eggs using a learned model generated in advance by supervised machine learning, and the egg images are stored in a storage unit. The egg images satisfying a condition set in advance are read from the storage unit according to a result of the determination, and displayed on a display unit.

Abstract: Disclosed are various embodiments related to automated cellular passaging of spheroids, tumoroids, organoids and/or other multi-cellular bodies. Organoids can be cultured in a hydrogel that is disposed in a well unit of a microwell plate. The well unit includes a primary well section that is fluidly connected to a secondary well section via at least one channel, and the hydrogel is disposed in the primary well section of the well unit. The hydrogel is dissipated into hydrogel fragments, thereby separating the organoids from the hydrogel. The hydrogel fragments are removed from the well unit, while the organoids remain in the well unit. The remaining organoids are broken into organoid fragments and corresponding debris. A fresh culture environment is created using the organoid fragments.

Abstract: A method of carrying out a bioreaction in a multivessel bioreactor system may include flowing a culture medium at an initial flow rate through one or more fluidic paths between a master vessel and one or more slave vessels, detecting a first culture medium parameter value in the master vessel or the slave vessels, transmitting the first culture medium parameter value to a control system, determining an adjusted flow rate of the culture medium at the control system based on the first culture medium parameter value, and controlling a bidirectional fluid transfer device with the control system to adjust the flow rate of the culture medium through the one or more fluidic paths. The control system may adjust the flow rate of the culture medium to maintain a substantially uniform value of the first culture medium parameter value in the master vessel or the one or more slave vessels.

Abstract: Systems and methods for producing and using a body having a first structure defining a first chamber, a second structure defining a second chamber, a membrane located at an interface region between the first chamber and the second chamber to separate the first chamber from the second chamber. The first chamber comprises a first permeable matrix disposed therein and the first permeable matrix comprises at least one or a plurality of lumens each extending therethrough, which is optionally lined with at least one layer of cells. The second chamber can comprise cells cultured therein. The systems and methods described herein can be used for various applications, including, e.g., growth and/or differentiation of primary cells, and/or simulation of a microenvironment in living tissues and/or organs (to model physiology or disease states, and/or to identify therapeutic agents). The systems and methods can also permit co-cultures of two or more different cell types.

Abstract: A cell culture container includes: an insert member having a membrane on which a cell is seeded, the insert member defining a first inner space that functions as an anaerobic chamber; a container having an attachment/detachment portion to and from which the insert member is attachable and detachable, the container defining a second inner space that functions as an aerobic chamber; a sealing member that closes an opening of the aerobic chamber between the attachment/detachment portion and the insert member with the insert member being attached to the attachment/detachment portion; and a transfer mechanism that transfers force to the sealing member. The sealing member closes the opening in response to an input of the force from the transfer mechanism.

Abstract: A method for functionalizing a hollow-fiber membrane for cell expansion of targeted cells (e.g., natural killer cells) includes contacting a biotinylating molecule to a surface of the hollow-fiber membrane including an extracellular matrix component, the biotinylating molecule binding to the extracellular matrix component and having an affinity for the targeted cells. The biotinylated molecule may be selected from the group consisting of: cytokine, epitope, ligand, monoclonal antibody, stains, aptamer, and combinations thereof. The extracellular matrix component may be selected from the group consisting of: fibronectin, vitronectin, fibrinogen, collagen, laminin, and combinations thereof.

Abstract: Miniature stirred tank bioreactor and system; the bioreactor configured for single use culturing, providing unobstructed culturing volume with sensors, probes and ports using minimally invasive placement in-wall or across the wall methods; the bioreactor further capable of containing scaffolds and features for culturing cells and tissue, including structures providing surfaces for cell growth, and screens for retaining microparticles during media exchange

Abstract: An electroporation apparatus has an electroporation probe terminals for linking with electrodes. A foam is injected at the treatment site to displace blood rather than mixing with it, increasing the contact time of a higher concentration of active agent with the tissue and thus resulting in greater efficacy. With foam solutions, a lower concentration of agent can be used to obtain the same therapeutic effect as in their liquid counterpart, reducing the prevalence of side effects associated with higher concentrations. A foam solution compared to an equivalent liquid solution enables more efficient cell electroporation particularly where bipolar pulses have been employed by mitigating an increase in tissue conductivity as would normally be observed with a comparable liquid solution. A more efficient cell permeabilisation would result in better results where electroporation is being delivered alone or as a tool to aid in the uptake of molecules into the cell.

Abstract: Disclosed are cell culture vessels capable of preventing the deformation of the culture vessels in a manipulation of taking in/out a cell or replacing a culture medium and preventing over-time increase in the concentration of carbon dioxide or and temporal decrease of pH of the culture medium and over-time temporal decrease of pH of the culture medium in cell culture as advantageous effects, and further parallel filter connectors for configuring such cell culture vessels. The cell culture vessels have two types of filters in parallel so as to partition a gas phase inside the cell culture vessel and the outer air, and the parallel filter connectors for configuring the cell culture vessels have an opening to be connected to the body of the cell culture vessel, and two openings capable to be installed with each one of the two types of different filters.

Abstract: The invention relates to a live cell culture incubator, a method of working with an incubator, and a system including an incubator. An image acquisition system is used to determine an occupancy of the incubator.

Abstract: The invention relates to a live cell culture incubator, a method of working with an incubator, and a system comprising an incubator in which an object tracking system is implemented.

Abstract: Provided is a cell culture system capable of detecting a proliferative property of cells in a culture vessel at a desired timing during a culture when the cells are statically cultured in the culture vessel formed of a gas permeable member. A cell culture system is a system for statically culturing cells with a culture vessel at least partially formed of a gas permeable member. The cell culture system includes an oxygen concentration sensor that measures an oxygen concentration in a vicinity of a culture surface inside the culture vessel, and a proliferation detection unit that detects a proliferative property of the cells based on an oxygen permeability of the gas permeable member, a measurement value of the oxygen concentration sensor, an oxygen concentration around the culture vessel, and an oxygen consumption per cell of the cells.

Abstract: A large scale bioreactor system includes a stainless steel large scale bioreactor having at least one valve assembly, and an aseptic connector assembly coupled to the at least one valve assembly of the bioreactor. A perfusion device includes an Alternating Tangential Filtration assembly with an autoclaved valve assembly coupled to the aseptic connector assembly, and the aseptic connector assembly includes one of a triclamp aseptic connector or a hose assembly. Single use feed containers include an aseptic connector assembly.

Abstract: The present invention relates to a method for controlling process parameters in a bioreactor when producing a target product with a pre-determined critical to quality, CTQ, profile. The method comprises: monitoring (S20) at least one product quality attribute, PQA, for the target product; identifying (S30) trends and/or deviations by comparing the monitored at least one PQA to the CTQ profile of the target product; and controlling (S40) process parameters of the bioreactor based on the identified trends and/or deviations to maintain the target product within the CTQ profile.

Abstract: The present invention relates to HS-LZ microalgae of the genus Chlorella (Chlorella sp. HS-LZ), which are novel microalgae characterized by being able to produce zeaxanthin and lutein, and uses thereof.

Abstract: There is described a process for producing at least one of mycoprotein and the components thereof, the process comprising: (i) providing a fermentation media suitable for producing mycoprotein; (ii) fermenting the fermentation media to obtain a mixture comprising mycoprotein; (iii) separating the mycoprotein from the mixture to obtain a mycoprotein phase; and (iv) mechanically disrupting the cell walls of the mycoprotein in the mycoprotein phase thereby releasing at least some of the mycoprotein cell contents. There is also described at least one of mycoprotein and the components thereof obtainable, obtained or directly obtained from the process. Further described is a composition comprising at least one of mycoprotein and the components thereof, wherein the composition is non-fibrous. The composition may comprise at least one of: protein obtained from mycoprotein, and amino acids derived from protein obtained from mycoprotein.

Abstract: The present disclosure provides engineered eukaryotic cells comprising a surface displayed catalytic domain of an endoglycosidase and methods of use.

Abstract: Provided herein are, inter alia, compositions, systems, kits, and methods for culturing and expanding cells (such as T cells, diploid or non-diploid cells), as well as methods for treating disorders (e.g., with T cells), and methods for producing biological molecules and compositions (e.g., proteins, viruses, viral particles or fragments thereof, etc.), including vaccines.

Abstract: Certain populations of small cells present in adult human tissue can undergo activation/development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation/development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

Abstract: The present invention provides a novel oocyte maturation medium or/and embryo culture medium with a chemically defined supplement to produce matured oocytes at high efficiency. The inventive medium or supplement comprises three growth factors, namely, fibroblast growth factor 2 (FGF2), leukemia inhibitory factor (LIF), and insulin-like growth factor 1 (IGF-1) in a synergistic combination. Methods for oocyte and embryo culture are also provided.

Abstract: Provided herein are, inter alia, are media compositions useful for culturing neural cells. In particular, the compositions provided herein mimic important physiological conditions in the living brain and sustain neural activity. The media compositions provided herein improve the efficiency of human neuron maturation and promote synaptic function in long-term in vitro cultures.

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

Abstract: The present invention is directed to methods for determining the likelihood that source tissue will be suitable for the generation of viable precursor cells.

Abstract: The present disclosure provides a model and method for rapid screening the efficacy of immunoregulatory drugs. The method comprises constructing an animal model containing PVDF capsule tubes, and further comprises analyzing the pharmacodynamic data for the animal model in vivo, phenotype identification by paired flow cytometry and multi-omics data. The PVDF capsule tubes have cells comprising tumor cells and immune cells in a single cell suspension; wherein the tumor cells and immune cells are derived from fresh tumor tissues or body fluids of clinical patients. The animal model constructed according to the present disclosure can be used for immune system targeting and drug efficacy regulation screening, and drug screening for multiple patients at the same time. It provides a rapid and effective method and model for clinical precision medicine and new drug development.

Abstract: Provided is a method for preparation of a composition comprising activated human CD4+ and CD8+ lymphocytes. The method entails use of allogeneic mature dendritic cells as feeder cells added at an early stage in the induction of proliferation and activation of CD4+ and CD8+ T cells. Further provided is a method for treatment of lymphopenia related diseases by infusion of the cells obtained from the present process.

Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.

Abstract: Methods of differentiating pluripotent stem cells into thymic epithelial progenitor cells are provided.

Abstract: A method of characterizing an effect of a compound on cardiomyocyte beating, including providing a system configured to culture, electrically pace, and monitor heating of beating cells: culturing two populations of immature cardiomyocytes in the system; adding a compound suspected of having an effect on cardiomyocyte maturation to one of the populations of immature cardiomyocytes; electrically pacing the two populations of immature cardiomyocytes according to a pulse profile that functionally matures immature cardiomyocytes until at least one of the two populations of cardiomyocytes is functionally mature; and Characterizing the compound as further driving maturation if the population with compound addition functionally matures before the other cardiomyocyte population.

Abstract: The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine.

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: Methods provided by the present disclosure utilize extracorporeal shockwaves, mechanical impacts and/or principles of lithotripsy to break up a tissue sample into smaller fragments—clusters of cells and/or single cells—after which a desired cellular fraction can be isolated from the sample. Devices provided by the present disclosure deploy focused and/or directed shockwaves, and/or focused and directed mechanical impacts, to break apart a tissue sample. The devices maintain the sample in a sterile, closed environment during exposure to the shockwaves or mechanical impacts. Therefore, the shockwaves and/or mechanical impacts are generated outside of a closed device and are transmitted through one or more walls of the device into its interior, where the sample is located.

Abstract: Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs.

Abstract: The disclosure relates to methods and tools for studying enteroendocrine cells, including intestinal reporter organoids, methods and media for making said organoids, uses of said organoids, and enteroendocrine cell targets and treatments.

Abstract: The present invention contemplates compositions, devices and methods of simulating biological fluids in a fluidic device, including but not limited to a microfluidic chip. In one embodiment, fluid comprising a colloid under flow in a microfluidic chip has a fluid density or viscosity similar to a bodily fluid, e.g. blood, lymph, lung fluid, or the like. In one embodiment, a fluid is provided as a rheologically biomimetic blood surrogate or substitute for simulating physiological shear stress and cell dynamics in fluidic device, including but not limited to immune cells.

Abstract: A directed evolution method for improving performance of a mammalian host cell is provided, as well as host cells generated using the directed evolution method. In one aspect, hydrogen peroxide (H2O2)-evolved host cells are provided. In one aspect, (H2O2)-evolved Chinese hamster ovary (CHO) host cells are provided.

Abstract: A WAYNE293 LVPRO cell adapted to a serum-free medium environment, and applications thereof are provided. The human embryonic kidney cell WAYNE 293 is preserved in China General Microbiological Culture Collection Center (CGMCC) on May 24, 2021, the address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Yard, Beichen West Road, Chaoyang District, Beijing, the postal code is 100101, and the preservation number is CGMCC No. 22348. The human embryonic kidney cell WAYNE 293 may be derived from suspension culture of HEK293 cells in a serum-free medium free of an anti-agglomeration agent, has the characteristics of short doubling time, high growth density, high virus packaging efficiency, and is an important support for industrial development in the field of cell and gene therapy.

Abstract: The present disclosure relates generally to the field of biotechnology and, in particular, to a cell culture membrane structure, cell culture apparatus comprising the cell culture membrane structure, methods for cell cultivation by using the cell culture apparatus, a cell culture incubator comprising the cell culture apparatus, and methods for producing the cell culture membrane structure.

Abstract: Described herein is the production neural progenitor cell lines (NPCs) derived from human induced pluripotent stem cells (iPSCs). These iPSC-derived NPCs engraft efficiently into the spinal cord of ALS animal models and provide neuroprotection to diseased motor neurons, similar to the fetal-derived cells used in clinical study. Clonal lines were generated with a single copy GDNF construct inserted in the AAVS1 safe landing site, including inducible expression of GDNF expression. These new iPSC-derived NPC lines are scalable to clinically relevant production volumes, uniformly produce GDNF, are safe, and represent a promising new combination therapy for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

Abstract: Disclosed herein are 3-D neural tissue structures or “brain organoids” created from human pluripotent cells (e.g., stem cells) differentiated into neuronal cell types that include cortical and subcortical neuronal subtypes along with sensory cells. Also disclosed herein are methods for the in vitro generation of 3-D neural tissue structures capable of sensory perception, methods for generating a “brain organoid-machine interface” (BOMI), and methods for screening of molecular, cellular and network-level defects associated with complex mental diseases through use of patient-derived induced pluripotent stem cells.

Abstract: The present invention relates to a method for removing host cell DNA from a sample comprising infectious viral particles and host cell DNA by anion exchange chromatography in the presence of at least one of a non-ionic surfactant, a sugar and a protein and to a method for purifying recombinant infectious viral particles from a host cell culture employing such an anion exchange chromatography step.

Abstract: Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.

Abstract: Provided are a PCR buffer composition for increasing the activity of a DNA polymerase having increased gene mutation specificity, a PCR kit for detecting a gene mutation or SNP comprising the PCR buffer composition and/or the DNA polymerase having increased gene mutation specificity, and a method for in vitro detecting one or more gene mutations or SNPs in one or more templates by using the kit.

Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.

Abstract: Tannase variants may be included in washing and cleaning agents, such as tannase variants with a sequence correspondingly similar to SEQ ID NO:1 and nucleic acids encoding them.

Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.

Abstract: Methods for labeling and imaging the accessible genome using a transposase are disclosed. In some embodiments, a bifunctional transposase complex or transposome is used to insert adaptors comprising chemical tags selectively at accessible sites in the genome where active regulatory DNA is located. Various chemical tags can be used for labeling DNA at insertion sites, including, for example, fluorescent dyes for fluorescence imaging, metal particles for electron microscopy or magnetic manipulation of DNA, isotopic labels, or biotin or other ligands, haptens, substrates, or inhibitors that are recognized by streptavidin, antibodies, enzymes, or receptors. Labeling DNA in this manner can be used to provide spatial information regarding the positioning of regulatory DNA in the genome and makes possible the imaging and sorting of cells based on the status of their regulatory DNA.

Abstract: The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject.